Authorship：Lead author   Language：English  

DOI： 10.1016/j.eclinm.2023.102303.

Language：English   Publisher：Respiratory Investigation  

Background: Non-small cell lung cancer (NSCLC) is diagnosed using small biopsy samples obtained by bronchoscopy or transthoracic lung core biopsy, and treated with immune checkpoint inhibitors, such as programmed cell death protein-1 (PD-1) and programmed cell death protein ligand-1 (PD-L1) inhibitors, as the first-line therapy. However, the clinical benefits of first-line PD-1/PD-L1 inhibitors in non-small cell carcinoma-not otherwise specified (NSCC–NOS) remain unclear. This study aimed to clarify the clinical efficacy of first-line PD-1/PD-L1 inhibitors in patients with NSCC-NOS. Methods: We retrospectively enrolled patients with recurrent or unresectable advanced NSCLC treated with first-line PD-1/PD-L1 inhibitors, with or without chemotherapy, at three medical institutions. We adjusted for patient characteristics using propensity score matching (PSM) and analyzed the impact of the histological subtype, NSCC-NOS, on survival outcomes in patients with NSCLC treated with immunotherapy. Results: Of the 312 eligible patients, 42 (13.5%) had a histological subtype of NSCC-NOS. Significantly more patients had PD-L1 ≥ 50% in the NSCC-NOS group than in the Non NSCC-NOS group (P = 0.01). After PSM, 41 patients with NSCC-NOS and 123 with other histological subtypes (Non NSCC-NOS) were analyzed. The median progression-free survival (PFS) and the median overall survival (OS) of patients with NSCC-NOS were significantly longer than those of patients with Non NSCC-NOS, respectively (median PFS: 14.8 vs. 6.1 months, P < 0.01; median OS: 33.4 vs. 15.1 months, P = 0.04, log-rank test). Conclusions: NSCC-NOS is a histological subtype that is highly responsive to first-line PD-1/PD-L1 inhibitors with or without chemotherapy.

DOI： 10.1016/j.resinv.2026.101383

Open Access

Web of Science

Scopus

PubMed

Language：English   Publisher：Journal of Chemotherapy  

The benefit of programmed cell death protein-1 (PD-1)/programmed cell death protein ligand-1 (PD-L1) inhibitors remains unclear in non-small cell lung cancer (NSCLC) patients with poor performance status (PS). In the current multi-centre retrospective cohort study, advanced or recurrent NSCLC patients treated with PD-1/PD-L1 inhibitors were enrolled. Of the 219 patients enrolled, 44 had PS 2–4. The objective response rate (ORR) of patients with PS 2–4 in 1^st line was 33%. Among 1^st line group, median progression-free survival (PFS) in patients with PS 2 was significantly longer compared to that in patients with PS 3–4 (15.3 months vs. 0.9 months, P = 0.039, Log-rank test). Among previously treated patients, the ORR of patients with PS 2–4 was only 4%, and PFS and overall survival was poor even in patients with PS 2. PD-1/PD-L1 inhibitors can be an option for PS 2 NSCLC patients in 1^st line setting.

DOI： 10.1080/1120009X.2025.2481349

Web of Science

Scopus

PubMed

Authorship：Lead author  

DOI： 10.1007/s00432-022-04300-x

Authorship：Lead author   Language：English